What recent performance tells you about Ocular Therapeutix (OCUL)

With no single headline event setting the tone, recent trading in Ocular Therapeutix (OCUL) reflects a mix of shorter term weakness and longer term gains that may catch investors’ attention.

The recent 1-day share price decline of 2.28% to US$11.55 follows a softer 30-day share price decline of 8.19%. However, the 1-year total shareholder return of 27.20% and the 3-year total shareholder return of a little over 3x indicate that longer term momentum has been stronger than the latest pullback suggests.

If Ocular Therapeutix has caught your eye, it can be helpful to compare it with other US healthcare names. healthcare stocks can serve as a ready list of ideas to review.

With recent short-term weakness, a 1-year return of 27.20% and an intrinsic value estimate implying a large discount, is Ocular Therapeutix still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 52.2% Undervalued

With Ocular Therapeutix last closing at US$11.55 against a narrative fair value of about US$24.17, the valuation gap rests heavily on future retinal programs and profitability assumptions.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Want to see how an aggressive revenue ramp, margin shift and premium future P/E all come together to justify that fair value gap? The full narrative spells out the numbers driving this view.

Result: Fair Value of $24.17 (UNDERVALUED)

However, this view hinges heavily on AXPAXLI. Any setback in key trials or tougher pricing pressure from payers could quickly challenge that upbeat narrative.

Another Angle on Valuation

The narrative fair value of about US$24.17 suggests Ocular Therapeutix might offer upside, but the current pricing tells a more complex story. On a P/S of 44.1x, the shares sit far above the US Pharmaceuticals industry at 4.5x, peers at 5.5x, and a fair ratio of 0.4x.

That kind of gap points to meaningful valuation risk if expectations around pipelines or revenue growth reset. The key question for you is whether Ocular’s future can comfortably fill the premium that today’s multiple implies.

Build Your Own Ocular Therapeutix Narrative

If you see the story differently, or prefer to test the assumptions yourself, you can build a custom view in minutes with Do it your way

A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Ocular Therapeutix is on your radar, do not stop there. Broaden your watchlist now so you are not late to other opportunities.

• Hunt for potential high-upside names using these 3553 penny stocks with strong financials that pair smaller share prices with stronger financial foundations.
• Zero in on the intersection of medicine and machine learning with these 29 healthcare AI stocks shaping the next wave of healthcare technology.
• Target companies analysts flag as potentially mispriced by tracking these 882 undervalued stocks based on cash flows based on projected cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.